Home
About Us
FAQ
Contact Us
Media Tools
ExpertConnect App
MyExpertNet
University Partners
Becoming a Partner
Key Organizations
Search Assistance
Help
Expert Profile
Views:
171
Share
QR code
Edit Profile
Karen Daily Weinstein
Clinical Professor
MD-HEMATOLOGY/ONCOLOGY | COLLEGE-MEDICINE
View:
Select
All (all in one)
Research Terms and Keywords
Publications
Co-Investigator Network
Websites
Contact
All
Research
Publications
Network
Websites
Contact
Research Terms & Keywords
Research Terms
Hematology
Research Projects
Ends
Title
02-2025
EAZ171
EAZ171
NRG ONCOLOGY FOU
05-2024
All-Extremity Exercise as a Novel Strategy for Optimizing Cardiovascular Function during Chemotherapy for Breast Cancer #######
All-Extremity Exercise as a Novel Strategy for Optimizing Cardiovascular Function during Chemotherapy for Breast Cancer #######
NATL INST OF HLTH NHLB
03-2024
Optimizing the Population Representativeness of Older Adults in Cancer Trials
Optimizing the Population Representativeness of Older Adults in Cancer Trials
NATL INST OF HLTH NC
02-2024
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
NATL INST OF HLTH NC
08-2023
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
NATL INST OF HLTH NC
08-2023
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
NRG ONCOLOGY FOU
06-2023
Risk of adverse cardiovascular events in breast cancer patients receiving systemic adjuvant therapy: impact of comorbidity burden
Risk of adverse cardiovascular events in breast cancer patients receiving systemic adjuvant therapy: impact of comorbidity burden
FL BREAST CANCER RES COALITION FO
10-2022
Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer
Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer
NATL INST OF HLTH NC
03-2022
CDK 4/6 inhibitors use among metastatic breast cancer patients: Early discontinuation and management of adverse events
CDK 4/6 inhibitors use among metastatic breast cancer patients: Early discontinuation and management of adverse events
PFIZER IN
12-2021
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
NATL INST OF HLTH NC
12-2021
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
NRG ONCOLOGY FOU
08-2021
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
NATL INST OF HLTH NC
08-2021
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
NRG ONCOLOGY FOU
06-2021
Early markers of subclinical pulmonary vascular radiation toxicity in breast cancer
Early markers of subclinical pulmonary vascular radiation toxicity in breast cancer
FL DEPT OF HLTH BANKHEAD-COLEY CANCER R
03-2021
Novel strategies to target disseminated tumor cells in triple negative breast cancer
Novel strategies to target disseminated tumor cells in triple negative breast cancer
FL DEPT OF HLTH BANKHEAD-COLEY CANCER R
03-2021
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
NATL INST OF HLTH NC
03-2021
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer
NRG ONCOLOGY FOU
03-2020
S1007, "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less"
S1007, "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less"
NATL INST OF HLT
03-2020
S1007, "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less"
S1007, "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less"
SOUTHWEST ONCOLOGY GROU
08-2019
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer
A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer
HOOSIER ONCOLOGY GROUP
05-2019
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
NATL INST OF HLTH NC
05-2019
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
NATL SURG ADJUV BREAST & BOWE
05-2019
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment withou
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment withou
NATL INST OF HLTH NC
05-2019
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment withou
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment withou
NRG ONCOLOGY FOU
02-2019
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy
NRG ONCOLOGY FOU
02-2019
A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL TUMOR...
A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL TUMOR...
NATL SURG ADJUV BREAST & BOWE
02-2019
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to
NATL INST OF HLTH NC
02-2019
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to
NATL SURG ADJUV BREAST & BOWE
09-2017
A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer
A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer
NATL SURG ADJUV BREAST & BOWE
09-2017
A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer
A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer
PUMA BIOTECHNOLOGY INC
07-2017
NSABP B-38 A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubincin/Cyclophosphamide (YAC): Dose-Dense (DD) Doxorubincin/Cyclophosmide Followed by DD Paclitaxel (DD AC P):
NSABP B-38 A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubincin/Cyclophosphamide (YAC): Dose-Dense (DD) Doxorubincin/Cyclophosmide Followed by DD Paclitaxel (DD AC P):
EASTERN COOP ONCOLOGY GROU
07-2017
NSABP B-38 A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubincin/Cyclophosphamide (YAC): Dose-Dense (DD) Doxorubincin/Cyclophosmide Followed by DD Paclitaxel (DD AC P):
NSABP B-38 A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubincin/Cyclophosphamide (YAC): Dose-Dense (DD) Doxorubincin/Cyclophosmide Followed by DD Paclitaxel (DD AC P):
NATL INST OF HLT
06-2017
Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)
Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)
NATL INST OF HLTH NC
06-2017
Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)
Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)
NRG ONCOLOGY FOU
05-2017
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Docetaxel in Combination with 1-methyl-D-tryptophan (indoximod) in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Docetaxel in Combination with 1-methyl-D-tryptophan (indoximod) in Metastatic Breast Cancer
NEW LINK GENETICS
05-2017
NSABP Protocol B-35 - A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in SITU (DCIS) Undergoing Lumpectomy with Radiation Therapy
NSABP Protocol B-35 - A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in SITU (DCIS) Undergoing Lumpectomy with Radiation Therapy
EASTERN COOP ONCOLOGY GROU
05-2017
NSABP Protocol B-35 - A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in SITU (DCIS) Undergoing Lumpectomy with Radiation Therapy
NSABP Protocol B-35 - A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in SITU (DCIS) Undergoing Lumpectomy with Radiation Therapy
NATL INST OF HLT
10-2016
NSABP Biospecimen Discovery Project (DP-1)
NSABP Biospecimen Discovery Project (DP-1)
BREAST CANCER RESEARCH FOU
10-2016
NSABP Biospecimen Discovery Project (DP-1)
NSABP Biospecimen Discovery Project (DP-1)
NATL SURG ADJUV BREAST & BOWE
06-2016
Preventing breast cancer recurrence through a tailored l
Preventing breast cancer recurrence through a tailored l
UF DSR OPPORTUNITY FUN
Publications
Search Google Scholar for Karen Daily Weinstein
OpenAlex Works Search
More Publications
"The transition years: what happens to adolescents on Medicaid who use mental health services?"
2000 ▪
Paul G. Stiles;
K. M. snyder; M Lo;
K. Daily;
https://openalex.org/W648582182
Co-Investigator Network
Inactive Expert
Andres Acosta
University of Florida
AG-FOOD SCIENCE / HUMAN NUTR, College- Agricul / Nat Res
-
Jiang Bian
Professor and Division Director of Biomedical Informatics; Chief Data Scientist & Chief Research Information Officer, UF Health
University of Florida
MD-HOBI-BIOMED INFORMATICS, College-Medicine
bianjiang@ufl.edu
Julie Bradley
Professor
University of Florida
MD-RADIATION ONCOLOGY, College-Medicine
juliekb@ufl.edu
Dejana Braithwaite
Professor and Division Chief, Population Health Sciences, Department of Surgery
University of Florida
MD-SURG-POPULATION HEALTH SCI, College-Medicine
dbraithwaite@ufl.edu
Demetra Christou
Associate Professor
University of Florida
HH-APK-ADMINISTRATION, College-Hlth/Human Performance
ddchristou@hhp.ufl.edu
Z. Hugh Fan
Professor
University of Florida
EG-Mechanical & Aerospace Engineering, College-Engineering
hfan@ufl.edu
Thomas George
AssociateProfessor - Physician
University of Florida
MD-HEMATOLOGY/ONCOLOGY, College-Medicine
tgeorge@ufl.edu
Inactive Expert
Bharatsinh Gharia
Assistant Professor
University of Florida
JX-MEDICINE AT JAX, College-Medicine Jacksonville
bharatsinh.gharia@jax.ufl.edu
Yi Guo
Associate Professor
University of Florida
MD-HOBI-GENERAL, College-Medicine
yiguo@ufl.edu
Eileen Handberg
ASSOC. PROFESSOR
University of Florida
MD-CARDIOLOGY, College-Medicine
handbem@medicine.ufl.edu
Coy Heldermon
Associate Professor
University of Florida
MD-HEMATOLOGY/ONCOLOGY, College-Medicine
coy.heldermon@medicine.ufl.edu
Danielle Jake-Schoffman
University of Florida
HH-HEB-ADMINISTRATION, College-Hlth/Human Performance
djakeschoffman@ufl.edu
Stephen Kimmel
Dean?s Professor and Chair
University of Florida
PHHP-COM EPIDEMIOLOGY, Phhp-Com Integrated Programs
skimmel@ufl.edu
Jorge Lascano
University of Florida
MD-PULMONARY MEDICINE, College-Medicine
jorge.lascano@medicine.ufl.edu
Ji-Hyun Lee
Professor & Associate Director for Cancer Quantitative Sciences
University of Florida
PHHP-COM BIOSTATISTICS, Phhp-Com Integrated Programs
jihyun.lee@ufl.edu
Inactive Expert
Zuofeng Li
Professor
University of Florida
EG-BIOMEDICAL ENGINEERING, College-Engineering
zuofeng@ufl.edu
Inactive Expert
Xiaoying Liang
University of Florida
MD-RADIATION ONCOLOGY, College-Medicine
xliang@floridaproton.org
Anne Mathews
Associate Professor
University of Florida
AG-DEAN FOR ACADEMIC PROGRAMS, College- Agricul / Nat Res
anne.mathews@ufl.edu
Walter O'Dell
Associate Professor
University of Florida
MD-RADIATION ONCOLOGY, College-Medicine
odelwg@shands.ufl.edu
Paul Okunieff
Professor and Chair
University of Florida
MD-RADIATION ONCOLOGY, College-Medicine
pokunieff@ufl.edu
Carl Pepine
Professor of Medicine, Division of Cardiovascular Medicine
University of Florida
Division of Cardiovascular Medicine, Medicine
pepincj@medicine.ufl.edu
Deidre Pereira
Associate Professor
University of Florida
Clinical and Health Psychology, College Of Public Health And Health Professions
dpereira@phhp.ufl.edu
Inactive Expert
Michael Perri
DEAN
University of Florida
OFFICE OF THE DEAN (PHHP), Public Health & Health Professions
mperri@phhp.ufl.edu
Inactive Expert
Alberto Riva
Associate Scientist
University of Florida
Interdisciplinary Center for Biotechnology Research, N/A
ariva@ufl.edu
Richard Segal
PROF & CHR
University of Florida
PH-PHARM OUTCOMES & POLICY, College-Pharmacy
segal@cop.ufl.edu
Karla Shelnutt
Assistant Professor and Extension Nutrition Specialist
University of Florida
AG-FAM YOUTH / COMM SCI, College- Agricul / Nat Res
kpagan@ufl.edu
Steven Swarts
Res Assoc Prof
University of Florida
MD-RAD ONCOLOGY RADIOBIOLOGY, College-Medicine
sgswarts@ufl.edu
Inactive Expert
David Tran
Chief, Co-Director and Professor
University of Florida
MD-NEUROSCIENCE, College-Medicine
david.tran@neurosurgery.ufl.edu
Xiang Zhong
Assistant Professor
University of Florida
EG-INDUSTRIAL / SYSTEMS ENG, College-Engineering
xiang.zhong@ise.ufl.edu
Inactive Expert
Fei Zou
University of Florida
PHHP-COM BIOSTATISTICS, Phhp-Com Integrated Programs
fayzou@ufl.edu
Websites
0000-0002-3218-9739
OpenAlex Works Search
Search Google Scholar for Karen Daily Weinstein
Contact Information
karen.daily@medicine.ufl.edu
3522737832
PO Box 100278 GAINESVILLE, FL 32610-0278
Profile QR code
What is this?
Keyword Search
Please enter valid search criteria.
Search
Centers
Experts
Projects
Speakers
Stories
Technologies
Videos
University
All Universities
Florida A&M University
Florida Atlantic University
Florida Gulf Coast University
Florida Institute of Technology
Florida International University
Florida State University
University of Central Florida
University of Florida
University of Miami
University of North Florida
University of South Florida
University of West Florida
Browse by STEM
Biotechnology
Computer Science
Energy
Engineering
Environmental Sciences
Information Science
Life Sciences
Mathematics
Medical Sciences
Military Sciences
Natural Sciences
Physical Sciences
Plant Sciences
Science
Space Sciences
Technology
Transportation
